Celldex plans FDA filing for barzolvolimab in 2027; analysts cut price targets
Celldex plans to seek FDA approval for barzolvolimab in chronic spontaneous urticaria in 2027 and is enrolling patients in phase 3 trials for cold urticaria and symptomatic dermographism. Barclays kept its overweight rating on Celldex (CLDX) but cut its price target to $50 from $53. HC Wainwright reiterated its buy rating and lowered its target to $58 from $64, 107.4% above the Nov. 19 close of $27.96.
In 35 seconds
- Celldex plans to seek FDA approval for barzolvolimab in chronic spontaneous urticaria in 2027.
- The company is enrolling patients in phase 3 trials for cold urticaria and symptomatic dermographism.
- Barclays keeps overweight but lowers its CLDX price target to $50 from $53.
IASummary generated by artificial intelligence from a story by TradingView. It may contain errors: the original source prevails.




Comments
Be respectful. Comments reported by several people are hidden until a moderator reviews them.
You do not need an account to read, only to comment. Sign in with a code sent to your email or with your Google account. We only show the name you choose, never your email.